Skytrofa Injection, Powder, Lyophilized, For Solution
Product Images NDC 73362-014

297 FDA label images from Ascendis Pharma Endocrinology, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 297 technical images submitted to the FDA as part of the official labeling for Skytrofa (NDC 73362-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascendis Pharma Endocrinology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image (Skytrofa 01)

Image (Skytrofa 01)
Skytrofa 3 mg injection, lyophilized powder for solution, label showing packaging for subcutaneous use. The box contains 4 single-dose cartridges and 6 sterile injection needles and is distributed by Ascendis Pharma, with illustrations of cartridges and needles. The label includes storage instructions, barcode, and information for use with the Skytrofa Auto-Injector kit.*
FDA Label Image

Image (Skytrofa 02)

Image (Skytrofa 02)
Packaging label for Skytrofa 3.6 mg injection, powder, lyophilized, for solution, containing lonapegsomatropin-tcgd. The label shows a box containing 4 single-dose cartridges and 6 sterile injection needles, designed for subcutaneous use. It includes the Ascendis Pharma Endocrinology, Inc. logo and information about storage and usage, with an illustration of the cartridges and needles visible on the package.*
FDA Label Image

Image (Skytrofa 03)

Image (Skytrofa 03)
Skytrofa 4.3 mg injection lyophilized powder carton for subcutaneous use containing lonapegsomatropin-tcgd. The box includes 4 single-dose cartridges and 6 sterile injection needles. The packaging is from Ascendis Pharma Endocrinology, Inc. and features product images, dosing information, handling instructions, and barcodes.*
FDA Label Image

Image (Skytrofa 04)

Image (Skytrofa 04)
Skytrofa 5.2 mg injection lyophilized powder vial packaging label for subcutaneous use. The box contains 4 single-dose cartridges and 6 sterile injection needles. The manufacturer is Ascendis Pharma Endocrinology, Inc. The label includes storage instructions, refrigeration requirements, and a barcode.*
FDA Label Image

Image (Skytrofa 05)

Image (Skytrofa 05)
Skytrofa 6.3 mg lyophilized powder injection for subcutaneous use. The carton contains 4 single-dose cartridges and 6 sterile injection needles. The label shows the active ingredient lonapegsomatropin-tcgd and specifies storage instructions, manufacturer Ascendis Pharma Endocrinology Division and distributor Ascendis Pharma, Inc. The packaging includes a barcode and areas for recording dates removed from refrigeration.*
FDA Label Image

Image (Skytrofa 06)

Image (Skytrofa 06)
Box packaging label for Skytrofa 7.6 mg injection powder, lyophilized, for subcutaneous use. The label shows it contains 4 single-dose cartridges and 6 sterile injection needles, distributed by Ascendis Pharma, Inc. The label includes storage instructions, barcode, and a depiction of the cartridges and needles.*
FDA Label Image

Image (Skytrofa 07)

Image (Skytrofa 07)
Packaging label for Skytrofa 9.1 mg injection, powder, lyophilized for solution by Ascendis Pharma Endocrinology, Inc. The box contains 4 single-dose cartridges and 6 sterile injection needles. The label includes product usage instructions, storage conditions, and a barcode. The packaging design features the Skytrofa logo, images of the cartridges and needles, and dosage information for subcutaneous administration.*
FDA Label Image

Image (Skytrofa 08)

Image (Skytrofa 08)
Skytrofa 11 mg injection, powder, lyophilized for solution in a carton with 4 single-dose cartridges and 6 sterile injection needles. The label shows the drug name Lonapegsomatropin-tcgd for injection, manufacturer Ascendis Pharma Endocrinology, Inc., and includes storage instructions along with a barcode. The packaging also notes the needles are 0.25 mm x 4 mm (31G x 5/32"). The product is for subcutaneous use and prescription only.*
FDA Label Image

Image (Skytrofa 09)

Image (Skytrofa 09)
Skytrofa 13.3 mg injection powder for solution in a lyophilized form, for subcutaneous use. The carton package includes 4 single-dose cartridges and 6 sterile injection needles. The label displays the product name, strength, form, dosage details, and manufacturer Ascendis Pharma Endocrinology, Inc. It also includes usage and storage instructions along with barcode and regulatory information.*
FDA Label Image

Image (Skytrofa 10)

FDA Label Image

Image (Skytrofa 11)

FDA Label Image

Image (Skytrofa 12)

FDA Label Image

Image (Skytrofa 13)

FDA Label Image

Image (Skytrofa 14)

FDA Label Image

Image (Skytrofa 15)

FDA Label Image

Image (Skytrofa 16)

FDA Label Image

Image (Skytrofa 17)

Image (Skytrofa 17)
An illustration showing a warning symbol (exclamation mark in a triangle) next to a syringe with 'zzz' symbols beside it, likely indicating caution related to sleepiness or sedation associated with injection use.*
FDA Label Image

Image (Skytrofa 18)

FDA Label Image

Image (Skytrofa 19)

Image (Skytrofa 19)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution for subcutaneous use. The label shows a circular vial with a cap, featuring the Skytrofa brand name and concentration of 5.2 mg/1. The vial is white with blue accents and includes Ascendis Pharma Endocrinology, Inc. as the labeler.*
FDA Label Image

Image (Skytrofa 20)

Image (Skytrofa 20)
Skytrofa cartridge and needle packaging. The image shows a single Skytrofa cartridge labeled with Ascendis Pharma, and a separate needle labeled B. Braun. The cartridge is a prefilled injection, powder for solution, intended for subcutaneous administration.*
FDA Label Image

Image (Skytrofa 21)

Image (Skytrofa 21)
An illustration showing components of the Skytrofa auto-injector system, including a charger, a USB to Micro-USB cable, a Quick Reference Guide booklet, an Auto-Injector Protective Cover, and the Skytrofa Auto-Injector device with a green cap. The items are labeled for easy identification.*
FDA Label Image

Image (Skytrofa 22)

Image (Skytrofa 22)
Skytrofa (lonapegsomatropin-tcgd) injection powder, lyophilized, for solution, available in multiple strengths. The label shows the proprietary and generic names, dosage form as injection powder for subcutaneous use, and is labeled by Ascendis Pharma Endocrinology, Inc. The image depicts a product carton with a blue and white design including dosage strength details.*
FDA Label Image

Image (Skytrofa 23)

FDA Label Image

Image (Skytrofa 24)

Image (Skytrofa 24)
Illustration showing a charger for an injection device with a battery icon indicating power status. The image appears related to a subcutaneous injection product but does not show medication packaging or labeling.*
FDA Label Image

Image (Skytrofa 25)

Image (Skytrofa 25)
The image shows two prefilled injection devices for Skytrofa (lonapegsomatropin-tcgd), a lyophilized powder for subcutaneous injection. The devices are designed for the delivery of the medication and feature a transparent barrel, markings for dosage measurement, and a needle protected with a cap. No strength or labeling details are visible on the devices themselves.*
FDA Label Image

Image (Skytrofa 26)

Image (Skytrofa 26)
An instructional illustration showing components for Skytrofa injection preparation. It includes a labeled sharps container, an alcohol wipe, a SKYTROFA cartridge by Ascendis Pharma, and a needle by B. Braun, displayed separately to indicate their use in subcutaneous administration.*
FDA Label Image

Image (Skytrofa 27)

FDA Label Image

Image (Skytrofa 28)

Image (Skytrofa 28)
The image shows two single-dose cartridges of Skytrofa, an injection powder for subcutaneous solution containing lonapegsomatropin-tcgd. Each cartridge has a clear barrel and a blue cap, designed for precise dosing. The product is labeled from Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 29)

FDA Label Image

Image (Skytrofa 30)

Image (Skytrofa 30)
Label for Skytrofa 5.2 mg injection, powder, lyophilized for solution, by Ascendis Pharma Endocrinology, Inc. The label shows the product name, generic name (Lonapegsomatropin-tcgd), strength of 5.2 mg, and indicates it is for injection. It includes a section for cartridge dose and expiration date in year-month format. A red stop sign icon advises not to remove part of the peel paper.*
FDA Label Image

Image (Skytrofa 31)

FDA Label Image

Image (Skytrofa 32)

FDA Label Image

Image (Skytrofa 33)

FDA Label Image

Image (Skytrofa 34)

Image (Skytrofa 34)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution. The label shows a carton with the brand name Skytrofa and the generic name Lonapegsomatropin-tcgd. This subcutaneous prescription drug is labeled by Ascendis Pharma Endocrinology, Inc. The front panel displays dosage strength, quantity (1 vial), and highlights it as a prescription medication.*
FDA Label Image

Image (Skytrofa 35)

Image (Skytrofa 35)
Skytrofa injection, powder, lyophilized, for solution, available in various strengths including 0.7 mg/1 to 13.3 mg/1. The packaging label shows multiple vials arranged in a tray, each vial labeled with product information including the proprietary name Skytrofa and manufacturer Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 36)

Image (Skytrofa 36)
An instructional diagram showing how to remove a cap from a vial. The image includes a vial cap with text indicating 'Sterile' and 'Rx only,' and a yellow arrow demonstrates the direction to twist or pull the cap off. The diagram is meant for vial preparation or access instructions, likely for reconstitution or injection use.*
FDA Label Image

Image (Skytrofa 37)

FDA Label Image

Image (Skytrofa 38)

FDA Label Image

Image (Skytrofa 39)

Image (Skytrofa 39)
An illustration showing a close-up view of a pre-filled injection pen or syringe with an orange double arrow spiraling around the needle end, indicating a twisting or locking mechanism for the injection device.*
FDA Label Image

Image (Skytrofa 40)

Image (Skytrofa 40)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, in a subcutaneous dosage form. The image shows a prefilled injection pen device used for administering the medication. Labeler is Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 41)

Image (Skytrofa 41)
Illustration showing instructions to operate the Skytrofa auto-injector device. It demonstrates pressing and releasing the green button to activate the auto-injector, with accompanying notes about hearing two loud beeps, the battery icon lighting up, and the green top flashing to indicate readiness.*
FDA Label Image

Image (Skytrofa 42)

Image (Skytrofa 42)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution for subcutaneous use. The image shows a white rectangular box with the Skytrofa brand name and product details. The label indicates various strength options and manufacturer Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 43)

Image (Skytrofa 43)
Skytrofa 3 mg/1 injection, powder, lyophilized, for solution, packaged in a single vial. The label shows the proprietary name Skytrofa and indicates subcutaneous use. The product is labeled by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 44)

FDA Label Image

Image (Skytrofa 45)

FDA Label Image

Image (Skytrofa 46)

Image (Skytrofa 46)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution in a single-dose vial. The label indicates the product is a human prescription drug containing lonapegsomatropin-tcgd, labeled by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 47)

Image (Skytrofa 47)
Skytrofa 5.2 mg/1 injection, powder, lyophilized, for solution is displayed in a clear vial with a blue and orange label. The vial shows the product name Skytrofa along with the strength 5.2 mg, indicating the dosage form as an injection powder. The label includes information related to subcutaneous administration and the manufacturer Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 48)

Image (Skytrofa 48)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder lyophilized for solution is shown in a vial packaging. The label on the vial is white with black text and features the product name, dosage form, and labeler Ascendis Pharma Endocrinology, Inc. The vial appears to be designed for subcutaneous injection.*
FDA Label Image

Image (Skytrofa 49)

Image (Skytrofa 49)
Instructional diagram showing steps to attach and secure the cartridge with needle to a Skytrofa injection device. Figure L demonstrates pushing the cartridge with attached needle into the flashing green top, Figure M shows clicking the cartridge into place indicated by the stop of flashing and battery icon switching off, and Figure N shows removing the finger from the cartridge after the click.*
FDA Label Image

Image (Skytrofa 50)

FDA Label Image

Image (Skytrofa 51)

FDA Label Image

Image (Skytrofa 52)

FDA Label Image

Image (Skytrofa 53)

Image (Skytrofa 53)
Skytrofa 2.5 mg/1 injection, powder, lyophilized for solution, for subcutaneous use. The vial label displays the proprietary name Skytrofa prominently, along with the active ingredient Lonapegsomatropin-tcgd. The packaging includes dosage strength information (2.5 mg/1) and is labeled by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 54)

FDA Label Image

Image (Skytrofa 55)

FDA Label Image

Image (Skytrofa 56)

FDA Label Image

Image (Skytrofa 57)

Image (Skytrofa 57)
Skytrofa with lonapegsomatropin-tcgd .7 mg/1 injection, powder, lyophilized, for solution for subcutaneous use. The label shows product and strength prominently along with directions for use, warnings, and storage instructions. Manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 58)

FDA Label Image

Image (Skytrofa 59)

FDA Label Image

Image (Skytrofa 60)

Image (Skytrofa 60)
An instructional illustration showing a clear cartridge for injection with an orange plug at one end. The image highlights that the orange plug may need to be removed from the cartridge, indicated by an arrow pointing away from the plug.*
FDA Label Image

Image (Skytrofa 61)

FDA Label Image

Image (Skytrofa 62)

Image (Skytrofa 62)
An instructional diagram showing the use of an auto-injector pen device. It instructs to wait 4 to 8 minutes for mixing the medicine by watching a progress bar gradually light up. The process concludes when two loud beeps sound and the entire progress bar flashes, indicating readiness for injection.*
FDA Label Image

Image (Skytrofa 63)

FDA Label Image

Image (Skytrofa 64)

Image (Skytrofa 64)
Skytrofa 9.1 mg/1 injection, powder, lyophilized, for solution for subcutaneous use. The image shows a white and blue carton containing one vial, with the labeler indicated as Ascendis Pharma Endocrinology, Inc. The packaging highlights the proprietary name Skytrofa and strength 9.1 mg, intended for human prescription drug use.*
FDA Label Image

Image (Skytrofa 65)

FDA Label Image

Image (Skytrofa 66)

Image (Skytrofa 66)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 3.6 mg strength. The label displays the product name, active ingredient, dosage form, and strength along with the labeler Ascendis Pharma Endocrinology, Inc. The packaging is primarily white with green accents and includes dosage information and storage instructions.*
FDA Label Image

Image (Skytrofa 67)

Image (Skytrofa 67)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized for solution, depicted as a single-dose vial silhouette. The image shows the outline of the vial used for subcutaneous administration, consistent with injectable drug products supplied by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 68)

Image (Skytrofa 68)
Skytrofa 3.6 mg/1 injection, powder, lyophilized, for solution for subcutaneous use. The packaging shows a multicolor carton with prominent blue and white panels, featuring the Skytrofa brand name and the Ascendis Pharma Endocrinology, Inc. labeler. The package includes product identification and dosage strength.*
FDA Label Image

Image (Skytrofa 69)

Image (Skytrofa 69)
Illustration showing usage instructions for Skytrofa injection pen. The sequence depicts holding and rotating the pen, then pressing to inject, followed by a music note indicating a waiting or completion signal.*
FDA Label Image

Image (Skytrofa 70)

Image (Skytrofa 70)
An instructional illustration showing a hand holding a syringe. The syringe is depicted with three small letter 'z's floating beside it, possibly indicating a state of rest or sleep.*
FDA Label Image

Image (Skytrofa 71)

Image (Skytrofa 71)
Skytrofa 2.1 mg injection powder, lyophilized for solution, designed for subcutaneous use. The carton displays the brand name "SKYTROFA" in bold blue lettering and indicates the dosage strength as 2.1 mg. The active ingredient, lonapegsomatropin-tcgd, is noted along with the labeler, Ascendis Pharma Endocrinology, Inc. Packaging includes a note about single-use and storage details.*
FDA Label Image

Image (Skytrofa 72)

FDA Label Image

Image (Skytrofa 73)

Image (Skytrofa 73)
Skytrofa 2.1 mg injection powder, lyophilized, for solution in a vial. The packaging shows a single vial labeled with the product name Skytrofa, the strength 2.1 mg, and states subcutaneous use. Manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 74)

Image (Skytrofa 74)
An instructional diagram showing two steps for using an auto-injector pen. Figure R depicts the auto-injector upright on a flat surface with instructions to keep it steady until two loud beeps are heard and a progress bar lights up. Figure S shows a hand pulling off the needle cover, with warnings not to twist it off and to keep it for later, noting an eye icon will light up.*
FDA Label Image

Image (Skytrofa 75)

FDA Label Image

Image (Skytrofa 76)

Image (Skytrofa 76)
Skytrofa (lonapegsomatropin-tcgd) injection, lyophilized powder for solution, 3 mg strength in a single-dose vial. The label includes dosage form, route of administration (subcutaneous), and is labeled by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 77)

FDA Label Image

Image (Skytrofa 78)

Image (Skytrofa 78)
Skytrofa 3 mg/1 injection, powder, lyophilized, for solution in a single-dose vial with a carton. The product is a subcutaneous injection containing lonapegsomatropin-tcgd, labeled by Ascendis Pharma Endocrinology, Inc. The carton and vial feature the Skytrofa branding in orange and blue tones.*
FDA Label Image

Image (Skytrofa 79)

Image (Skytrofa 79)
Skytrofa 3 mg/1 injection, powder, lyophilized, for solution, supplied in a vial labeled with the product name and strength. The label includes the active ingredient Lonapegsomatropin-tcgd and indicates subcutaneous administration. Manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 80)

FDA Label Image

Image (Skytrofa 81)

Image (Skytrofa 81)
An illustration showing a syringe with a needle, accompanied by three 'Z' symbols indicating sleep or rest. This diagram likely represents an injection procedure related to the product's subcutaneous route of administration.*
FDA Label Image

Image (Skytrofa 82)

Image (Skytrofa 82)
Skytrofa 7.6 mg lonapegsomatropin-tcgd injection, powder, lyophilized, for solution in a single-dose vial. The package includes a syringe with a needle and additional components, designed for subcutaneous use. Labeling shows Ascendis Pharma Endocrinology, Inc. as the manufacturer.*
FDA Label Image

Image (Skytrofa 83)

Image (Skytrofa 83)
Instructional illustration depicting the inspection of a Skytrofa (Lonapegsomatropin-tcgd) injection device. The left side shows the medicine is acceptable if it is colorless, clear, and may contain air bubbles. The right side warns not to use the medicine if visible particles are present, advising to press the green button for 8 seconds and proceed to the next step.*
FDA Label Image

Image (Skytrofa 84)

FDA Label Image

Image (Skytrofa 85)

FDA Label Image

Image (Skytrofa 86)

Image (Skytrofa 86)
Skytrofa injection powder, lyophilized for solution, in a single-dose vial. The label shows the proprietary name Skytrofa and the generic name lonapegsomatropin-tcgd. The vial is white with a purple label and includes strength and manufacturer details for Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 87)

Image (Skytrofa 87)
An instructional diagram showing recommended subcutaneous injection sites on the human body. The front view highlights the stomach (abdomen) and thighs, while the back view indicates the buttocks as appropriate injection areas.*
FDA Label Image

Image (Skytrofa 88)

FDA Label Image

Image (Skytrofa 89)

Image (Skytrofa 89)
An illustration showing two hands being washed with soap and water, depicted with bubbles around the hands to indicate cleaning.*
FDA Label Image

Image (Skytrofa 90)

FDA Label Image

Image (Skytrofa 91)

FDA Label Image

Image (Skytrofa 92)

FDA Label Image

Image (Skytrofa 93)

FDA Label Image

Image (Skytrofa 94)

Image (Skytrofa 94)
An instructional illustration showing a hand applying a cleansing wipe to a skin area, likely preparing the site for subcutaneous injection. The image depicts proper skin cleaning technique before administering an injection, relevant to injectable medications such as Skytrofa (lonapegsomatropin-tcgd).*
FDA Label Image

Image (Skytrofa 95)

Image (Skytrofa 95)
An instructional illustration showing the use of the Skytrofa auto-injector for subcutaneous injection. Figure X demonstrates pressing and holding the green top against the injection site for 10 to 20 seconds until two loud beeps are heard, with the green top flashing twice and a check mark lighting up. Figure Y shows removing the auto-injector from the skin and waiting for two loud beeps while the green top flashes, indicating completion of the injection process.*
FDA Label Image

Image (Skytrofa 96)

Image (Skytrofa 96)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution in a vial. The package displays the brand name Skytrofa prominently, with the active ingredient Lonapegsomatropin-tcgd noted. It is labeled for subcutaneous use and provided by Ascendis Pharma Endocrinology, Inc. The vial contains a single-dose lyophilized powder for injection.*
FDA Label Image

Image (Skytrofa 97)

FDA Label Image

Image (Skytrofa 98)

Image (Skytrofa 98)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution is presented in a single-dose vial. The label indicates it is a subcutaneous human prescription drug manufactured by Ascendis Pharma Endocrinology, Inc. The vial label clearly shows the proprietary name, strength, dosage form, and route of administration.*
FDA Label Image

Image (Skytrofa 99)

FDA Label Image

Image (Skytrofa 100)

Image (Skytrofa 100)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 3 mg per vial. The bottle label includes the brand name Skytrofa prominently, with dosage strength and quantity visible. The label also shows the route of administration as subcutaneous injection and lists Ascendis Pharma Endocrinology, Inc. as the labeler.*
FDA Label Image

Image (Skytrofa 101)

FDA Label Image

Image (Skytrofa 102)

Image (Skytrofa 102)
Skytrofa 2.5 mg/1 injection, lyophilized powder for solution for subcutaneous use. The label shows the proprietary name Skytrofa with the nonproprietary name Lonapegsomatropin-tcgd. The labeler is Ascendis Pharma Endocrinology, Inc. The label includes the strength 2.5 mg and instructions related to dosing and administration.*
FDA Label Image

Image (Skytrofa 103)

Image (Skytrofa 103)
Instructional illustration showing how to remove the cartridge from an injection device. The first step depicts pressing down the needle cover into the flashing green top until a click is heard to release the cartridge. The second step shows removing the used cartridge from the device.*
FDA Label Image

Image (Skytrofa 104)

FDA Label Image

Image (Skytrofa 105)

FDA Label Image

Image (Skytrofa 106)

Image (Skytrofa 106)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, in a subcutaneous dosage form. The packaging is a white and light yellow carton with text in black and orange, featuring the Ascendis Pharma Endocrinology, Inc. labeler name. This image shows a single-use vial package with a strength of 5.2 mg/1 as part of the available strengths.*
FDA Label Image

Image (Skytrofa 107)

FDA Label Image

Image (Skytrofa 108)

Image (Skytrofa 108)
Skytrofa 2.5 mg injection, powder, lyophilized, for solution, in a vial. The label shows the proprietary name Skytrofa and the active ingredient Lonapegsomatropin-tcgd, indicated for subcutaneous use. The labeler is Ascendis Pharma Endocrinology, Inc. The vial volume and other specific numeric details are not clearly visible.*
FDA Label Image

Image (Skytrofa 109)

Image (Skytrofa 109)
Instructional illustration showing a used injection cartridge with a needle being discarded into a sharps disposal container. The image includes text directing to check that the cartridge is empty before disposal.*
FDA Label Image

Image (Skytrofa 110)

FDA Label Image

Image (Skytrofa 111)

Image (Skytrofa 111)
Skytrofa 3 mg/1 injection, powder, lyophilized, for solution vial. The vial has a blue cap and a label with black text detailing the product name, strength, dosage form, and manufacturer Ascendis Pharma Endocrinology, Inc. The vial contains a single dose for subcutaneous administration.*
FDA Label Image

Image (Skytrofa 112)

FDA Label Image

Image (Skytrofa 113)

FDA Label Image

Image (Skytrofa 114)

Image (Skytrofa 114)
The image shows two prefilled syringes containing Skytrofa (lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution. These subcutaneous injection syringes display the active drug in a clear, liquid form inside transparent barrels with attached needles. No specific strength is visible. The product is labeled by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 115)

Image (Skytrofa 115)
An instructional illustration showing a hand placing a protective cover on an auto-injector device. Text advises storing the auto-injector at room temperature between 59°F and 86°F (15°C to 30°C) for readiness of next use.*
FDA Label Image

Image (Skytrofa 116)

Image (Skytrofa 116)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution vial with a purple cap. The vial label shows the proprietary name Skytrofa, strength 2.5 mg/1, and indicates it is for subcutaneous use. The label also includes the manufacturer, Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 117)

Image (Skytrofa 117)
Skytrofa 13.3 mg/1 injection powder vial label for subcutaneous use. The lyophilized powder is presented in a single-dose vial. Label shows the brand name Skytrofa, active ingredient Lonapegsomatropin-tcgd, strength 13.3 mg/1, and is manufactured by Ascendis Pharma Endocrinology, Inc. The vial label includes storage instructions and lot number details.*
FDA Label Image

Image (Skytrofa 118)

Image (Skytrofa 118)
The image shows a pharmaceutical vial labeled Skytrofa containing Lonapegsomatropin-tcgd injection powder for solution. The vial is clear glass with a silver-colored cap and a white label. The label includes text indicating the product name and dosage form. The product is manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 119)

Image (Skytrofa 119)
Skytrofa 2.1 mg injection, powder, lyophilized, for solution, in a vial with a pink cap. The label includes the product name, strength, dosage form, and labeler Ascendis Pharma Endocrinology, Inc. The packaging is designed for subcutaneous administration.*
FDA Label Image

Image (Skytrofa 120)

Image (Skytrofa 120)
Skytrofa 2.5 mg/1 injection powder vial for lyophilized solution, intended for subcutaneous use. The vial label includes the proprietary name Skytrofa, the active ingredient Lonapegsomatropin-tcgd, strength 2.5 mg/1, and identifies Ascendis Pharma Endocrinology, Inc. as the labeler.*
FDA Label Image

Image (Skytrofa 121)

Image (Skytrofa 121)
Illustration showing a Skytrofa injection device with a green cap and button. The image highlights green flashing icons on the device screen, including checkmark, eye, and circular arrow symbols, and a green battery icon, indicating user prompts related to device status or alerts.*
FDA Label Image

Image (Skytrofa 122)

Image (Skytrofa 122)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, subcutaneous use. The label shows the product name, dosage form, and manufacturer Ascendis Pharma Endocrinology, Inc. Specific strength details are not visible on the image.*
FDA Label Image

Image (Skytrofa 123)

Image (Skytrofa 123)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, available in multiple strengths. The packaging includes multiple white cartons of Skytrofa with blue and orange labeling, showing the brand name prominently, with dosage strength indicated on each box. The product is labeled for subcutaneous use and manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 124)

FDA Label Image

Image (Skytrofa 125)

Image (Skytrofa 125)
Skytrofa 2.1 mg vial label featuring Lonapegsomatropin-tcgd injection, powder, lyophilized, for solution for subcutaneous use. The label shows the product name, strength, and dosage form prominently, along with the Ascendis Pharma Endocrinology, Inc. labeler name and various regulatory and safety information.*
FDA Label Image

Image (Skytrofa 126)

Image (Skytrofa 126)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution. The label shows a vial with a pink cap containing the lyophilized powder for subcutaneous injection. The label includes the proprietary and generic names, strength blanks for selection, and the Ascendis Pharma Endocrinology, Inc. labeler information. The vial is designed for dosing flexibility with multiple strengths available.*
FDA Label Image

Image (Skytrofa 127)

Image (Skytrofa 127)
Skytrofa 0.7 mg/1 injection, powder, lyophilized for solution, subcutaneous use. The label displays the proprietary name Skytrofa prominently with dosage strength .7 mg/1 indicated. The labeler is Ascendis Pharma Endocrinology, Inc. The packaging is a clear cylindrical vial with a pinkish cap and printed text on a white background.*
FDA Label Image

Image (Skytrofa 128)

Image (Skytrofa 128)
Skytrofa 0.7 mg/1 injection, powder, lyophilized, for solution, subcutaneous use. The label features the brand name Skytrofa prominently along with its generic name, lonapegsomatropin-tcgd. The label indicates it is a human prescription drug produced by Ascendis Pharma Endocrinology, Inc. Identification numbers and barcodes are also visible on the label.*
FDA Label Image

Image (Skytrofa 129)

Image (Skytrofa 129)
Skytrofa 3 mg/1 injection powder, lyophilized, for subcutaneous use. The label displays the proprietary name Skytrofa and nonproprietary name Lonapegsomatropin-tcgd. It is labeled as a human prescription drug by Ascendis Pharma Endocrinology, Inc. The image shows vial packaging with clear dosage and product details.*
FDA Label Image

Image (Skytrofa 130)

Image (Skytrofa 130)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, shown in packaging with multiple single-dose vial cartons. Available strengths include 0.7 mg, 1.4 mg, 1.8 mg, 11 mg, 13.3 mg, 2.1 mg, 2.5 mg, 3 mg, 3.6 mg, 4.3 mg, 5.2 mg, 6.3 mg, 7.6 mg, and 9.1 mg per vial. The labeler is Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 131)

Image (Skytrofa 131)
Skytrofa 2.5 mg/1 injection powder, lyophilized, for solution subcutaneous use. The carton features the Ascendis Pharma Endocrinology, Inc. labeler, with product strength and name prominently displayed on a white and teal colored background.*
FDA Label Image

Image (Skytrofa 132)

Image (Skytrofa 132)
Skytrofa 9.1 mg/1 injection, powder, lyophilized, for solution. The carton displays the brand name Skytrofa along with the strength 9.1 mg/1 visible. It is for subcutaneous use and labeled by Ascendis Pharma Endocrinology, Inc. The packaging includes dosage form and route information clearly on the front panel.*
FDA Label Image

Image (Skytrofa 133)

Image (Skytrofa 133)
An instructional diagram illustrating the correct orientation for using a pen-style injection device. The central image shows the pen held upright vertically labeled as "ok" with a green arrow, while two tilted positions of the pen, leaning left and right and marked with red Xs, indicate incorrect usage orientations.*
FDA Label Image

Image (Skytrofa 134)

Image (Skytrofa 134)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, multiple vial strengths are displayed including 9.1 mg/1 and others, all for subcutaneous use. The labels show the product name, dosage form, strength, and the labeler Ascendis Pharma Endocrinology, Inc. The vials have white caps and clear glass bodies with printed information.*
FDA Label Image

Image (Skytrofa 135)

Image (Skytrofa 135)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 13.3 mg strength in a single-dose vial. The label includes product and manufacturer details, dosage form, and storage information. Manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 136)

Image (Skytrofa 136)
Skytrofa injection, powder, lyophilized, for solution in a single-dose vial. The label displays the brand name Skytrofa prominently along with the generic name lonapegsomatropin-tcgd. The dosage strength is 5.2 mg per vial. The product is labeled for subcutaneous use and manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 137)

Image (Skytrofa 137)
An instructional illustration showing a hand holding a Skytrofa injection device poised for subcutaneous administration. The diagram emphasizes positioning the needle end against the skin to deliver the lyophilized powder solution by injection.*
FDA Label Image

Image (Skytrofa 138)

Image (Skytrofa 138)
Skytrofa 2.5 mg injection, lyophilized powder for subcutaneous solution, shown in a multi-dose vial with accompanying packaging. Label displays the proprietary name, active ingredient lonapegsomatropin-tcgd, dosage strength 2.5 mg, and the labeler Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 139)

Image (Skytrofa 139)
Skytrofa 3.6 mg/1 injection, powder, lyophilized, for solution, in a vial. The label includes the proprietary name Skytrofa and the nonproprietary name lonapegsomatropin-tcgd. The product is intended for subcutaneous administration. It is labeled by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 140)

Image (Skytrofa 140)
Skytrofa 3 mg/1 injection, powder, lyophilized for solution in a vial with a purple cap. The vial label shows the proprietary name Skytrofa, strength 3 mg, and indicates the dosage form for subcutaneous use. The product is labeled by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 141)

Image (Skytrofa 141)
Skytrofa 5.2 mg lyophilized powder for injection with a single-dose vial and a small clear syringe, meant for subcutaneous administration. This product is labeled by Ascendis Pharma Endocrinology, Inc. The packaging includes a cardboard carton showing the product name and strength.*
FDA Label Image

Image (Skytrofa 142)

FDA Label Image

Image (Skytrofa 143)

Image (Skytrofa 143)
An instructional illustration showing a close-up of a device with a green button and a rectangular orange indicator light at the base. The image includes a black arrow pointing to the orange light, which is also highlighted glowing, indicating attention or activation. A power adapter with an electrical plug icon is connected via a cord to the device.*
FDA Label Image

Image (Skytrofa 144)

FDA Label Image

Image (Skytrofa 145)

Image (Skytrofa 145)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 3.6 mg strength shown on the label. The packaging indicates it is a single-dose vial with the labeler Ascendis Pharma Endocrinology, Inc. Subcutaneous use is specified.*
FDA Label Image

Image (Skytrofa 146)

Image (Skytrofa 146)
Skytrofa (Lonapegsomatropin-tcgd) injection powder, lyophilized, for solution, subcutaneous use. The label shows the product name, strength, and dosage form. It is labeled by Ascendis Pharma Endocrinology, Inc. The packaging is primarily white with orange and black text detailing the product information and usage instructions.*
FDA Label Image

Image (Skytrofa 147)

Image (Skytrofa 147)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 3.6 mg strength vial pictured with accompanying vial size information and manufacturer Ascendis Pharma Endocrinology, Inc. The label includes dosage and administration details along with storage instructions.*
FDA Label Image

Image (Skytrofa 148)

Image (Skytrofa 148)
Skytrofa 3.0 mg injection, powder, lyophilized, for solution in a single-use vial. The label shows the brand name Skytrofa, the active ingredient Lonapegsomatropin-tcgd, strength of 3 mg, dose form for subcutaneous injection, and the manufacturer Ascendis Pharma Endocrinology, Inc. The vial is capped and designed for reconstitution before use.*
FDA Label Image

Image (Skytrofa 149)

Image (Skytrofa 149)
Skytrofa (lonapegsomatropin-tcgd) injection, powder, lyophilized for solution, labeled with strength 6.3 mg/1. The white carton features the brand and generic names, with the Ascendis Pharma Endocrinology, Inc. labeler name displayed. The box is designed for subcutaneous use and includes multiple dosing strengths.*
FDA Label Image

Image (Skytrofa 150)

FDA Label Image

Image (Skytrofa 151)

Image (Skytrofa 151)
Skytrofa (lonapegsomatropin-tcgd) 3.6 mg injection, powder, lyophilized, for solution in a vial. The carton displays the product name, strength, and dosing information, indicating it is manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 152)

Image (Skytrofa 152)
Skytrofa injection, lyophilized powder for solution, containing Lonapegsomatropin-tcgd. The label includes dosage strength of 13.3 mg per vial and indicates subcutaneous administration. The packaging prominently displays the brand name Skytrofa and the manufacturer Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 153)

Image (Skytrofa 153)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized for solution, subcutaneous use. The label shows a single-dose vial containing 1.4 mg of active ingredient. The labeler is Ascendis Pharma Endocrinology, Inc. The vial label includes dosing and product information.*
FDA Label Image

Image (Skytrofa 154)

Image (Skytrofa 154)
Skytrofa (lonapegsomatropin-tcgd) injection, powder, lyophilized, for subcutaneous solution. The carton shows the brand name Skytrofa prominently along with the injectable dosage form and powder specification. It is labeled by Ascendis Pharma Endocrinology, Inc. The image displays the outer packaging with the label information visible but does not specify the exact strength.*
FDA Label Image

Image (Skytrofa 155)

Image (Skytrofa 155)
Skytrofa 2.5 mg lyophilized powder for solution injection, containing lonapegsomatropin-tcgd, presented in a single-dose vial with a blue cap. Label shows dosage strength and administration route as subcutaneous. Manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 156)

Image (Skytrofa 156)
Skytrofa injection, powder, lyophilized, for solution by Ascendis Pharma Endocrinology, Inc. The label shows the product name Skytrofa prominently with the generic name Lonapegsomatropin-tcgd. Dosage strength displayed is 2.5 mg. The container appears to be a vial with the label including directions for use and concentration details, intended for subcutaneous use.*
FDA Label Image

Image (Skytrofa 157)

Image (Skytrofa 157)
Skytrofa 3 mg/1 injection, powder, lyophilized for solution, subcutaneous use. The carton displays the proprietary name Skytrofa and the active ingredient lonapegsomatropin-tcgd. The label shows the product strength of 3 mg/1 and indicates it is for subcutaneous injection. The labeler is Ascendis Pharma Endocrinology, Inc. The package size includes 1 vial.*
FDA Label Image

Image (Skytrofa 158)

Image (Skytrofa 158)
Skytrofa 5.2 mg/1 vial injection, powder, lyophilized, for solution for subcutaneous use. The carton shows the product name Skytrofa, active ingredient lonapegsomatropin-tcgd, strength 5.2 mg/1, and identifies the labeler as Ascendis Pharma Endocrinology, Inc. The package contains one vial.*
FDA Label Image

Image (Skytrofa 159)

Image (Skytrofa 159)
Chemical structure diagram showing the molecular structure of Lonapegsomatropin-tcgd, the active ingredient in Skytrofa. The structure includes detailed bonds and ring formations typical of the compound's chemical formula.*
FDA Label Image

Image (Skytrofa 160)

Image (Skytrofa 160)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution for subcutaneous use. The image shows a white and blue vial labeled for Skytrofa by Ascendis Pharma Endocrinology, Inc. The vial label includes text identifying the drug and usage form but does not specify strength or package size.*
FDA Label Image

Image (Skytrofa 161)

Image (Skytrofa 161)
Skytrofa (lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution in a 3 mL vial. The label shows the product name, generic name, vial size, and manufacturer Ascendis Pharma Endocrinology, Inc. The strength on this vial appears to be 3 mg/1, intended for subcutaneous use.*
FDA Label Image

Image (Skytrofa 162)

Image (Skytrofa 162)
Skytrofa 6.3 mg/1 injection, powder, lyophilized, for solution in a single-dose vial. The vial contains 6.3 mg of lonapegsomatropin-tcgd for subcutaneous use. Labeled by Ascendis Pharma Endocrinology, Inc., the vial label includes lot number, expiry date, and barcodes.*
FDA Label Image

Image (Skytrofa 163)

Image (Skytrofa 163)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 13.3 mg strength vial shown. The label includes the brand and generic names, dosage form, strength, and the labeler Ascendis Pharma Endocrinology, Inc. The vial has a green cap and a clear glass body with a white and green label displaying the key product information.*
FDA Label Image

Image (Skytrofa 164)

Image (Skytrofa 164)
An illustration showing a vertical slider bar with a checkmark, an eye symbol, and a refresh or reload icon alongside it, possibly depicting controls or settings adjustment.*
FDA Label Image

Image (Skytrofa 165)

FDA Label Image

Image (Skytrofa 166)

FDA Label Image

Image (Skytrofa 167)

Image (Skytrofa 167)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution, subcutaneous. The packaging is a white carton with blue accents, prominently showing the product name Skytrofa and strength 2.5 mg. The labeler is Ascendis Pharma Endocrinology, Inc. The box includes dosage and preparation instructions and appears to contain a single vial.*
FDA Label Image

Image (Skytrofa 168)

FDA Label Image

Image (Skytrofa 169)

Image (Skytrofa 169)
An instructional diagram depicting an eye and a vertical liquid level indicator with a check mark, suggesting verification or monitoring of liquid level in a vial or syringe. Green arrows indicate the liquid level for visibility. The design implies a step related to preparing or inspecting a subcutaneous injection solution.*
FDA Label Image

Image (Skytrofa 170)

Image (Skytrofa 170)
Skytrofa 2.5 mg lyophilized powder for solution injection, subcutaneous use. The carton front displays the brand name Skytrofa prominently with the dosage strength of 2.5 mg. Labeler is Ascendis Pharma Endocrinology, Inc. Additional labeling includes dosage form and instructions for reconstitution, with vehicle volume noted as 0.5 mL. The packaging is primarily white with blue and orange elements.*
FDA Label Image

Image (Skytrofa 171)

Image (Skytrofa 171)
An instructional graphic showing a stylized vertical device or vial with a check mark, an eye symbol, and a circular arrow indicating steps or status. The image suggests verifying or monitoring, possibly related to device or medication preparation or usage.*
FDA Label Image

Image (Skytrofa 172)

Image (Skytrofa 172)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution for subcutaneous use. The packaging is a white carton from Ascendis Pharma Endocrinology, Inc. The front displays the brand name Skytrofa along with the strength 2.5 mg prominently on the front panel. Additional text includes the nonproprietary name Lonapegsomatropin-tcgd and dosage form details.*
FDA Label Image

Image (Skytrofa 173)

Image (Skytrofa 173)
An instructional diagram showing a vertical thermometer-like scale with an eye icon, a checkmark at the top, and a circular green arrow symbol at the bottom. The scale appears to indicate a process or status, possibly related to observation or verification steps.*
FDA Label Image

Image (Skytrofa 174)

Image (Skytrofa 174)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, in a single-dose vial. The label indicates a 3.6 mg/1 strength and the product is for subcutaneous use. The labeler is Ascendis Pharma Endocrinology, Inc. The vial includes dosage instructions and storage information on the label.*
FDA Label Image

Image (Skytrofa 175)

Image (Skytrofa 175)
An instructional illustration showing a vertical syringe window with a checkmark next to the upper level, an eye symbol beside the middle level, and a circular arrow at the bottom, likely indicating steps or statuses for proper injection or solution preparation involving the product Skytrofa (Lonapegsomatropin-tcgd).*
FDA Label Image

Image (Skytrofa 176)

Image (Skytrofa 176)
Skytrofa 5.2 mg/1 injection is a lyophilized powder for solution by Ascendis Pharma Endocrinology, Inc. The front carton displays the brand name Skytrofa prominently and specifies the strength as 5.2 mg per vial, for subcutaneous use. The label includes the manufacturer name and dosage form details.*
FDA Label Image

Image (Skytrofa 177)

Image (Skytrofa 177)
An instructional diagram showing a vertical slider scale with a check mark at the top, an eye symbol indicating observation, and a circular arrow symbol representing a refresh or repeat action. The slider has multiple notches, likely indicating adjustable levels or settings.*
FDA Label Image

Image (Skytrofa 178)

Image (Skytrofa 178)
Skytrofa 3 mg/1 injection, powder, lyophilized, for solution vial label. The label shows the proprietary name Skytrofa and the active ingredient Lonapegsomatropin-tcgd. Manufactured by Ascendis Pharma Endocrinology, Inc., it is intended for subcutaneous use. The vial label includes strength and usage instructions consistent with a prescribed human prescription drug.*
FDA Label Image

Image (Skytrofa 179)

FDA Label Image

Image (Skytrofa 180)

FDA Label Image

Image (Skytrofa 181)

Image (Skytrofa 181)
Skytrofa 3 mg/1 injection, powder, lyophilized, for solution is shown in this image. The product is a subcutaneous human prescription drug by Ascendis Pharma Endocrinology, Inc. The label includes the proprietary and generic names along with dosing information visible on the vial.*
FDA Label Image

Image (Skytrofa 182)

Image (Skytrofa 182)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution in a 1 mL vial. The label shows the product name Skytrofa with active ingredient Lonapegsomatropin-tcgd. It is labeled for subcutaneous use and manufactured by Ascendis Pharma Endocrinology, Inc. This vial is intended for human prescription use.*
FDA Label Image

Image (Skytrofa 183)

Image (Skytrofa 183)
Skytrofa 2.1 mg/1 injection, powder, lyophilized, for solution for subcutaneous use. The packaging shows a white carton with blue and teal text and graphics, labeled with the brand name Skytrofa and the active ingredient lonapegsomatropin-tcgd. The labeler is Ascendis Pharma Endocrinology, Inc. The image depicts a single-dose vial alongside the carton.*
FDA Label Image

Image (Skytrofa 184)

FDA Label Image

Image (Skytrofa 185)

FDA Label Image

Image (Skytrofa 186)

FDA Label Image

Image (Skytrofa 187)

FDA Label Image

Image (Skytrofa 188)

FDA Label Image

Image (Skytrofa 189)

FDA Label Image

Image (Skytrofa 190)

FDA Label Image

Image (Skytrofa 191)

Image (Skytrofa 191)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 2.5 mg strength. The image shows a single vial with a green cap within a blister card. The label includes the product name, strength, dosage form, and manufacturer Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 192)

FDA Label Image

Image (Skytrofa 193)

FDA Label Image

Image (Skytrofa 194)

Image (Skytrofa 194)
Skytrofa 3.0 mg/1 injection, powder, lyophilized, for solution in a vial. The label shows the brand name Skytrofa prominently along with the dosage strength. Manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 195)

FDA Label Image

Image (Skytrofa 196)

FDA Label Image

Image (Skytrofa 197)

FDA Label Image

Image (Skytrofa 198)

Image (Skytrofa 198)
Chemical structure diagram showing the molecular structure of Lonapegsomatropin-tcgd, the active ingredient in Skytrofa injection.*
FDA Label Image

Image (Skytrofa 199)

Image (Skytrofa 199)
Skytrofa 13.3 mg/1 Injection, Powder, Lyophilized, for Solution for Subcutaneous use. The packaging includes the proprietary name Skytrofa and the generic name Lonapegsomatropin-tcgd. The vial shows the strength of 13.3 mg/1, with the labeler listed as Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 200)

Image (Skytrofa 200)
Skytrofa 9.1 mg/1 injection, powder, lyophilized for solution, subcutaneous use. The white carton with blue and green accents shows the proprietary name Skytrofa prominently, with the active ingredient Lonapegsomatropin-tcgd noted underneath. The labeler is Ascendis Pharma Endocrinology, Inc. The package is designed for prescription human drug use.*
FDA Label Image

Image (Skytrofa 201)

FDA Label Image

Image (Skytrofa 202)

Image (Skytrofa 202)
Skytrofa 13.3 mg injection powder, lyophilized, for solution, in a single-dose vial. The label shows dosage strength, route as subcutaneous injection, and manufacturer Ascendis Pharma Endocrinology, Inc. The vial is clear with a white and green label, including dosage and administration details.*
FDA Label Image

Image (Skytrofa 203)

Image (Skytrofa 203)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, in a 6.3 mg/1 vial. The vial label shows the product name, strength, and the labeler Ascendis Pharma Endocrinology, Inc. The vial is clear with a pale blue cap and label text in black and blue.*
FDA Label Image

Image (Skytrofa 203a)

Image (Skytrofa 203a)
Skytrofa lyophilized powder injection for solution, available in various strengths including 0.7 mg and up to 13.3 mg per vial, for subcutaneous use. The product is labeled by Ascendis Pharma Endocrinology, Inc. The label shows dosage strength, route, and regulatory information on a white background with minimalist design.*
FDA Label Image

Image (Skytrofa 203b)

Image (Skytrofa 203b)
Skytrofa 3 mg/1 injection, powder, lyophilized, for solution in a vial. The label shows the proprietary name Skytrofa with the active ingredient lonapegsomatropin-tcgd. It is indicated as a subcutaneous injection by Ascendis Pharma Endocrinology, Inc. No additional dosing or packaging details are visible in the image.*
FDA Label Image

Image (Skytrofa 204)

Image (Skytrofa 204)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution in a vial. The label shows the proprietary name Skytrofa with the active ingredient lonapegsomatropin-tcgd. The dosage form is for subcutaneous use, and the labeler is Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 205)

FDA Label Image

Image (Skytrofa 206)

FDA Label Image

Image (Skytrofa 207)

FDA Label Image

Image (Skytrofa 208)

FDA Label Image

Image (Skytrofa 209)

FDA Label Image

Image (Skytrofa 210)

FDA Label Image

Image (Skytrofa 211)

FDA Label Image

Image (Skytrofa 212)

FDA Label Image

Image (Skytrofa 213)

FDA Label Image

Image (Skytrofa 214)

FDA Label Image

Image (Skytrofa 215)

FDA Label Image

Image (Skytrofa 216)

FDA Label Image

Image (Skytrofa 217)

FDA Label Image

Image (Skytrofa 218)

Image (Skytrofa 218)
A temperature range indicator illustration showing temperatures of 15°C (59°F) at the bottom and 30°C (86°F) at the top, possibly indicating recommended storage conditions or temperature limits for a pharmaceutical product.*
FDA Label Image

Image (Skytrofa 219)

Image (Skytrofa 219)
An illustration showing a vertical temperature range scale from -10°C to 40°C (14°F to 104°F). This diagram likely indicates the recommended storage temperature range for the product.*
FDA Label Image

Image (Skytrofa 220)

FDA Label Image

Image (Skytrofa 221)

FDA Label Image

Image (Skytrofa 222)

Image (Skytrofa 222)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, subcutaneous dosage form. The image shows a rectangular carton labeled with the product name Skytrofa, manufactured by Ascendis Pharma Endocrinology, Inc. The carton background is predominantly white with shades of blue and green. The specific strength is not legible on the visible portion of the packaging.*
FDA Label Image

Image (Skytrofa 223)

FDA Label Image

Image (Skytrofa 224)

FDA Label Image

Image (Skytrofa 225)

FDA Label Image

Image (Skytrofa 226)

FDA Label Image

Image (Skytrofa 227)

Image (Skytrofa 227)
Chemical structure diagram of lonapegsomatropin-tcgd, the active ingredient in Skytrofa. The diagram depicts molecular bonds and atoms in a detailed and complex arrangement representative of this compound's molecular formula.*
FDA Label Image

Image (Skytrofa 228)

FDA Label Image

Image (Skytrofa 229)

FDA Label Image

Image (Skytrofa 230)

Image (Skytrofa 230)
A label featuring a 2D Data Matrix barcode accompanied by four separate lines of numeric and alphanumeric codes, likely representing product identification and batch information for Skytrofa (Lonapegsomatropin-tcgd) injection.*
FDA Label Image

Image (Skytrofa 231)

Image (Skytrofa 231)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized for solution, in a vial with a purple cap. The label shows the product name, active ingredient, and manufacturer's name, Ascendis Pharma Endocrinology, Inc. The vial appears to be a single-dose container. Strength is not legible.*
FDA Label Image

Image (Skytrofa 232)

Image (Skytrofa 232)
An instructional diagram for the Skytrofa auto-injector for subcutaneous injection. The image highlights key features including the green top to start injection, inspection window for mixed medicine, progress bar indicating mixing and injection status, and status icons for injection completion, medicine readiness, and mixing. It also details the green button to operate the injector, needle attachment instructions, and battery status indicator colors with their meanings. The SKYTROFA cartridge containing medicine and water is shown separately along with an orange plug.*
FDA Label Image

Image (Skytrofa 233)

FDA Label Image

Image (Skytrofa 234)

Image (Skytrofa 234)
Illustration showing a portion of a Skytrofa injection pen with a green cap and a white body. The pen features a dosage indicator window with symbols including a check mark and an eye, as well as an up arrow button, representing dose setting and injection controls for the lyophilized powder for solution injection device.*
FDA Label Image

Image (Skytrofa 235)

Image (Skytrofa 235)
An illustration featuring a QR code centered inside a rounded square with an orange border. Above the QR code, the text reads 'Watch Video.' Below the QR code, the URL 'www.skytrofa.com' is shown. The image directs users to watch a video about Skytrofa through scanning the QR code or visiting the website.*
FDA Label Image

Image (Skytrofa 236a)

Image (Skytrofa 236a)
Instructions for Use for Skytrofa (lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution. The image features icons for Instructions for Use, Quick Reference Guide, and Training Video available at www.skytrofa.com. It includes Ascendis Pharma Customer Support contact information, distributor details for Ascendis Pharma Endocrinology Inc. and Phillips-Medisize A/S in Denmark, and notes FDA approval with an issued date of July, 2026.*
FDA Label Image

Image (Skytrofa 240)

Image (Skytrofa 240)
Illustration of the Skytrofa auto-injector device showing labeled parts including the green top that starts injection, the inspection window for viewing mixed medicine, a progress bar with six light elements, and status icons indicating injection status. The green button turns the device on or rejects medicine. Also shown are components like the needle, orange plug, and Skytrofa cartridge containing medicine and water for injection.*
FDA Label Image

Image (Skytrofa 241)

Image (Skytrofa 241)
Skytrofa 3.6 mg/1 Injection, Powder, Lyophilized, for Solution for Subcutaneous use. The label shows the brand name Skytrofa prominently with the strength 3.6 mg. The active ingredient Lonapegsomatropin-tcgd is indicated. The label includes usage instructions, dosage strength, and manufacturing details by Ascendis Pharma Endocrinology, Inc. The packaging is green and white with clear dosage and preparation details.*
FDA Label Image

Image (Skytrofa 242)

Image (Skytrofa 242)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, subcutaneous use. The carton displays the brand name Skytrofa prominently along with the dosage strength of 2.1 mg/1 vial. The labeler is Ascendis Pharma Endocrinology, Inc. The packaging is white with blue and orange accents.*
FDA Label Image

Image (Skytrofa 243)

Image (Skytrofa 243)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized for solution, in a cardboard carton. The label includes the product name, dosage form, and manufacturer Ascendis Pharma Endocrinology, Inc. Strength details are not clearly visible on the image. The packaging presents a white and teal color scheme with a distinctive white circle design.*
FDA Label Image

Image (Skytrofa 244)

FDA Label Image

Image (Skytrofa 245)

Image (Skytrofa 245)
Skytrofa 3 mg/1 injection, powder, lyophilized for solution. The carton displays the product name Skytrofa, the generic name Lonapegsomatropin-tcgd, and dosage strength of 3 mg per vial. It is labeled for subcutaneous administration and distributed by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 246)

Image (Skytrofa 246)
Skytrofa (Lonapegsomatropin-tcgd) injection powder, lyophilized, for solution, in a vial packaging. The label indicates the product is a human prescription drug intended for subcutaneous use. The labeler is Ascendis Pharma Endocrinology, Inc. The vial features a green and white color scheme with clear branding and text.*
FDA Label Image

Image (Skytrofa 247)

Image (Skytrofa 247)
Skytrofa 6.3 mg/1 injection powder, lyophilized, for subcutaneous solution in a vial. The label shows the proprietary name Skytrofa and the manufacturer Ascendis Pharma Endocrinology, Inc. This packaging is for a human prescription drug containing lonapegsomatropin-tcgd.*
FDA Label Image

Image (Skytrofa 248)

Image (Skytrofa 248)
Skytrofa 7.6 mg/1 injection, powder, lyophilized, for solution in a vial. The label shows the proprietary name Skytrofa, the strength 7.6 mg/1, and the manufacturer Ascendis Pharma Endocrinology, Inc. The vial is partially visible and appears to have a white or light-colored cap with a green and white label.*
FDA Label Image

Image (Skytrofa 249)

Image (Skytrofa 249)
Pack contains two cartons of Skytrofa (lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, at 11 mg strength per vial. Each carton shows a single-dose vial image and the labeler is Ascendis Pharma Endocrinology, Inc. The packaging is designed for subcutaneous administration.*
FDA Label Image

Image (Skytrofa 250)

Image (Skytrofa 250)
Illustration showing a vertical device with a lightning bolt symbol and a connected cable, accompanied by an arrow pointing left and an orange indicator light icon, likely depicting a step or status related to device operation or charging.*
FDA Label Image

Image (Skytrofa 251)

Image (Skytrofa 251)
Skytrofa 3 mg/1 injection lyophilized powder for solution, subcutaneous administration. The packaging includes the product name, strength, dosage form, and the labeler Ascendis Pharma Endocrinology, Inc. The container is white with blue and gold labeling, and the vial is visible next to the box.*
FDA Label Image

Image (Skytrofa 252)

Image (Skytrofa 252)
Skytrofa 3.6 mg injection, lyophilized powder for solution, for subcutaneous use. The package includes a single vial with product name and strength, manufactured by Ascendis Pharma Endocrinology, Inc. The box design features text and regulatory information in blue and white color schemes.*
FDA Label Image

Image (Skytrofa 253)

Image (Skytrofa 253)
An instructional illustration showing the correct upright position for the Skytrofa injection pen. The pen is centered and vertical with a green "ok" above it, indicating proper orientation. Two tilted positions of the pen to the left and right have red "x" marks, indicating incorrect handling angles.*
FDA Label Image

Image (Skytrofa 254)

FDA Label Image

Image (Skytrofa 255)

Image (Skytrofa 255)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution in a vial and carton by Ascendis Pharma Endocrinology, Inc. The label includes the proprietary and generic names, dose strength, route (subcutaneous), and storage instructions. The vial is amber-colored with a purple cap.*
FDA Label Image

Image (Skytrofa 256)

Image (Skytrofa 256)
An instructional illustration showing a hand holding an injection pen with a green tip, positioned to administer a subcutaneous injection by pressing the tip against the skin. An arrow indicates the downward motion of the pen toward the injection site.*
FDA Label Image

Image (Skytrofa 257)

Image (Skytrofa 257)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 3.6 mg strength. The vial label shows the product name, strength, dosage form, and is manufactured by Ascendis Pharma Endocrinology, Inc. The label includes identifying markings and dosing information in a clear, concise format.*
FDA Label Image

Image (Skytrofa 258)

Image (Skytrofa 258)
An instructional diagram showing locations of the expiration date and cartridge dose on a Skytrofa injection cartridge. The expiration date is indicated in a YYYY-MM format, and the cartridge dose is clearly labeled on the cartridge itself. The image highlights these labels for user reference.*
FDA Label Image

Image (Skytrofa 259)

Image (Skytrofa 259)
An instructional diagram showing where to check the expiration date on the product container's cap. The expiration date format is indicated as year, month, and day (YYYY-MM-DD).*
FDA Label Image

Image (Skytrofa 260)

FDA Label Image

Image (Skytrofa 261)

Image (Skytrofa 261)
Skytrofa (lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution in a prefilled disposable injector device. The image shows a single-dose pen-style injector used for subcutaneous administration, designed for accurate dosing of this human prescription drug. Manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 262)

Image (Skytrofa 262)
An instructional illustration showing how to operate the Skytrofa auto-injector device. It depicts a hand pressing and releasing the green button on the device to turn the auto-injector on, with the device shown before and after activation.*
FDA Label Image

Image (Skytrofa 263)

FDA Label Image

Image (Skytrofa 264)

Image (Skytrofa 264)
Skytrofa 2.5 mg/1 injection, powder, lyophilized, for solution for subcutaneous use. The label displays the brand name Skytrofa prominently, with the active ingredient Lonapegsomatropin-tcgd and strength of 2.5 mg underlined. Manufactured by Ascendis Pharma Endocrinology, Inc. The label includes details like dosage form, administration route, and identification numbers.*
FDA Label Image

Image (Skytrofa 265)

Image (Skytrofa 265)
An instructional illustration showing a hand pushing down a cartridge with an attached needle featuring a flashing green top into an injection device. The diagram labels the needle and cartridge components, indicating the correct assembly for use.*
FDA Label Image

Image (Skytrofa 266)

Image (Skytrofa 266)
An instructional illustration demonstrating the assembly of a Skytrofa injection device. The image shows a hand placing a cartridge onto the injector with a green top that stops flashing when correctly attached. A mixing icon lights up, and the battery icon switches on to indicate readiness.*
FDA Label Image

Image (Skytrofa 267)

Image (Skytrofa 267)
An instructional illustration showing a close-up of a finger removing a cartridge from a Skytrofa injection device. The image includes a green and white Skytrofa pen injector with an emphasis on proper cartridge removal after activation.*
FDA Label Image

Image (Skytrofa 268)

Image (Skytrofa 268)
An instructional illustration showing two views of a white injection device with green accents. The image directs to wait 4 to 8 minutes between steps, indicated by arrows and a clock symbol, demonstrating part of the preparation or administration process for the injectable product.*
FDA Label Image

Image (Skytrofa 269)

FDA Label Image

Image (Skytrofa 270)

Image (Skytrofa 270)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 13.3 mg strength is shown in a vial packaging. The label includes key product information and is manufactured by Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 271)

Image (Skytrofa 271)
An instructional illustration showing hand manipulation of a cylindrical injection device. The sequence involves rotating the device, holding it firmly to induce a 'tick' sound, followed by activation indicated with a musical note symbol, suggesting readiness or completion of a step in the injection preparation process.*
FDA Label Image

Image (Skytrofa 272)

Image (Skytrofa 272)
Skytrofa (Lonapegsomatropin-tcgd) injection, powder, lyophilized, for solution, 2.1 mg strength, subcutaneous use. The packaging includes a white carton with green and blue accents, displaying the brand name Skytrofa prominently, along with the active ingredient lonapegsomatropin-tcgd and dosage strength. The labeler is Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Image (Skytrofa 273)

Image (Skytrofa 273)
An illustration of a white and green injection device with a slim, vertical design and a green cap at the top. A blue speech bubble with a white musical note icon is shown next to the device, suggesting an audio or alert feature related to the device operation.*
FDA Label Image

Image (Skytrofa 274)

Image (Skytrofa 274)
An instructional diagram illustrating how to remove the needle cover from a subcutaneous injection device. It shows a hand pulling off the needle cover with a caution note not to twist it, and advises to keep the needle cover for later use. There is also an indication that an eye icon on the device will light up.*
FDA Label Image

Image (Skytrofa 275)

Image (Skytrofa 275)
An instructional diagram showing a medication cartridge and its inspection before use. The left side depicts a cartridge with colorless, clear liquid possibly containing air bubbles, marked as acceptable with an 'ok' in green. The right side shows a cartridge with visible particles, marked with an 'x' in red, advising not to use the mixed medicine if particles are present and to press the green button for 8 seconds as a next step.*
FDA Label Image

Image (Skytrofa 276)

Image (Skytrofa 276)
An illustration showing recommended subcutaneous injection sites for Skytrofa (Lonapegsomatropin-tcgd). The front view highlights the stomach (abdomen) and thighs, while the back view indicates the buttocks as injection areas.*
FDA Label Image

Image (Skytrofa 277)

Image (Skytrofa 277)
An illustration depicting two hands with soap bubbles, suggesting hand washing or hand hygiene. The hands are positioned with palms facing each other, covered in foam or soap, emphasizing cleaning action.*
FDA Label Image

Image (Skytrofa 278)

Image (Skytrofa 278)
Illustration showing a hand pressing a cotton ball or gauze pad onto skin, demonstrating a step commonly associated with preparing an injection site, such as cleaning or applying pressure after injection.*
FDA Label Image

Image (Skytrofa 279)

Image (Skytrofa 279)
An instructional illustration showing a hand holding an injection device with a green top pressed against the skin. Text instructions indicate to press and hold the green top against the injection site for 10 to 20 seconds until two loud beeps are heard and the green top flashes twice. A check mark icon is shown to indicate successful activation.*
FDA Label Image

Image (Skytrofa 280)

Image (Skytrofa 280)
An instructional illustration showing a hand holding an auto-injector with a green tip pressed against skin. The image includes text instructing to remove the auto-injector from the skin and wait for two loud beeps. Visual indicators include a green top flashing and sound symbols representing beeps and vibration.*
FDA Label Image

Image (Skytrofa 281)

Image (Skytrofa 281)
An instructional illustration demonstrating how to remove the cartridge from an injection device. The image shows two hands pressing down the needle cover onto the flashing green top of the device until a click sound is heard, indicating the cartridge can be removed.*
FDA Label Image

Image (Skytrofa 282)

Image (Skytrofa 282)
Instructional illustration showing a hand removing a used cartridge from a device, indicated by an upward arrow and the text "Remove used cartridge." The image likely relates to the preparation or administration process of a medication.*
FDA Label Image

Image (Skytrofa 283)

Image (Skytrofa 283)
An instructional diagram showing proper disposal of used cartridges and needles into a sharps container, accompanied by a note about managing weekly doses requiring two cartridges with steps for repeated injections using new cartridges and needles from the Skytrofa injection system.*
FDA Label Image

Image (Skytrofa 284)

Image (Skytrofa 284)
An instructional illustration showing a hand placing a protective cover on an auto-injector device, with a recommendation to store the auto-injector at room temperature between 59°F to 86°F (15°C to 30°C) for readiness of next use.*
FDA Label Image

Principal Display Panel (3 mg Cartridge Blister Pack Carton)

Principal Display Panel (3 mg Cartridge Blister Pack Carton)
Skytrofa 3 mg injection powder, lyophilized, for subcutaneous use, containing lonapegsomatropin-tcgd. The carton includes 4 single-dose cartridges and 6 sterile injection needles, manufactured and labeled by Ascendis Pharma Endocrinology, Inc. Directions state refrigeration required and that the product should not be frozen, with usage instructions for trained users only.*
FDA Label Image

Principal Display Panel (3.6 mg Cartridge Blister Pack Carton)

Principal Display Panel (3.6 mg Cartridge Blister Pack Carton)
Skytrofa 3.6 mg injection powder, lyophilized, for subcutaneous use. The carton contains 4 single-dose cartridges and 6 sterile injection needles. Manufactured by Ascendis Pharma Endocrinology Division A/S, distributed by Ascendis Pharma Endocrinology Inc. Storage instructions and product warnings are printed on the label.*
FDA Label Image

Principal Display Panel (4.3 mg Cartridge Blister Pack Carton)

Principal Display Panel (4.3 mg Cartridge Blister Pack Carton)
Skytrofa 4.3 mg injection powder, lyophilized for solution, carton label with 4 single-dose cartridges and 6 sterile injection needles. The label shows the product's proprietary and generic name, includes storage instructions, contents, and manufacturer Ascendis Pharma Endocrinology, Inc. The label highlights subcutaneous use and includes a barcode with lot and expiration date fields.*
FDA Label Image

Principal Display Panel (5.2 mg Cartridge Blister Pack Carton)

Principal Display Panel (5.2 mg Cartridge Blister Pack Carton)
Skytrofa 5.2 mg injection, powder, lyophilized for solution, designed for subcutaneous use. The box contains 4 single-dose cartridges and 6 sterile injection needles. Labeled by Ascendis Pharma Endocrinology, Inc., the packaging includes storage instructions, a barcode, and notes on proper handling and use with the Skytrofa auto-injector device.*
FDA Label Image

Principal Display Panel (6.3 mg Cartridge Blister Pack Carton)

Principal Display Panel (6.3 mg Cartridge Blister Pack Carton)
Packaging label for Skytrofa 6.3 mg injection, powder, lyophilized for solution, subcutaneous use. This box contains 4 single-dose cartridges and 6 sterile injection needles. The label includes storage instructions, lot and expiration date placeholders, and manufacturer information for Ascendis Pharma Endocrinology, Inc.*
FDA Label Image

Principal Display Panel (7.6 mg Cartridge Blister Pack Carton)

Principal Display Panel (7.6 mg Cartridge Blister Pack Carton)
Skytrofa 7.6 mg injection lyophilized powder for solution in a box containing 4 single-dose cartridges and 6 sterile injection needles. The label includes storage and handling instructions, manufacturer Ascendis Pharma Endocrinology, Inc., and directions to refrigerate the cartridges but not freeze. Barcode and lot number areas are visible on the packaging.*
FDA Label Image

Principal Display Panel (9.1 mg Cartridge Blister Pack Carton)

Principal Display Panel (9.1 mg Cartridge Blister Pack Carton)
Skytrofa 9.1 mg (lonapegsomatropin-tcgd) injection, lyophilized powder for subcutaneous use, shown as a flat packaging label. The label indicates a box containing 4 single-dose cartridges and 6 sterile injection needles, by Ascendis Pharma Endocrinology, Inc. The label includes usage instructions, storage conditions, and a barcode, with images of the cartridges and needles.*
FDA Label Image

Principal Display Panel (11 mg Cartridge Blister Pack Carton)

Principal Display Panel (11 mg Cartridge Blister Pack Carton)
Skytrofa 11 mg injection lyophilized powder for subcutaneous use in a box containing 4 single-dose cartridges and 6 sterile injection needles. The label shows the brand and generic name (lonapegsomatropin-tcgd), manufacturer Ascendis Pharma Endocrinology, Inc., and storage instructions. It includes a barcode and lot/expiration date placeholder.*
FDA Label Image

Principal Display Panel (13.3 mg Cartridge Blister Pack Carton)

Principal Display Panel (13.3 mg Cartridge Blister Pack Carton)
Skytrofa 13.3 mg injection, lyophilized powder for solution, in a box containing 4 single-dose cartridges and 6 sterile injection needles. The label shows multiple images of cartridges and needles, and includes storage instructions, manufacturer information (Ascendis Pharma Endocrinology Division A/S), and barcode. Designed for subcutaneous use, with detailed handling and discard guidance printed on the outer carton.*
FDA Label Image

Principal Display Panel (0.7 mg Cartridge Blister Pack Box)

Principal Display Panel (0.7 mg Cartridge Blister Pack Box)
Skytrofa 0.7 mg injection powder for solution, lyophilized, subcutaneous use. The carton label shows the brand name Skytrofa with the generic name lonapegsomatropin-tcgd. The package contains 4 single-dose cartridges and 6 sterile injection needles. Labeler is Ascendis Pharma Endocrinology, Inc. Storage instructions include refrigeration at 2°C to 8°C. The label includes usage and disposal instructions along with manufacturer information.*
FDA Label Image

Principal Display Panel (1.4 mg Cartridge Blister Pack Box)

Principal Display Panel (1.4 mg Cartridge Blister Pack Box)
Skytrofa 1.4 mg injection powder, lyophilized for solution in a carton label. Contains 4 single-dose cartridges and 6 sterile injection needles, for subcutaneous use. Distributed and manufactured by Ascendis Pharma Endocrinology, Inc. The label includes storage instructions to refrigerate at 2°C to 8°C and warnings against use without training. NDC 73362-013-01.*
FDA Label Image

Principal Display Panel (1.8 mg Cartridge Blister Pack Box)

Principal Display Panel (1.8 mg Cartridge Blister Pack Box)
Skytrofa 1.8 mg injection powder, lyophilized, for subcutaneous use. The carton includes 4 single-dose cartridges and 6 sterile injection needles. Labeler is Ascendis Pharma Endocrinology, Inc. The packaging features usage instructions, storage conditions, and a depiction of cartridges and needles.*
FDA Label Image

Principal Display Panel (2.1 mg Cartridge Blister Pack Box)

Principal Display Panel (2.1 mg Cartridge Blister Pack Box)
Skytrofa 2.1 mg (lonapegsomatropin-tcgd) injection, lyophilized powder for solution, subcutaneous use. The unfolded carton box label shows the product name and dosage strength prominently, with images of 4 single-dose cartridges and 6 sterile injection needles included in the package. The labeler is Ascendis Pharma Endocrinology, Inc. The packaging includes storage instructions, directions to use only under healthcare provider supervision, and details for reconstitution and dosage.*
FDA Label Image

Principal Display Panel (2.5 mg Cartridge Blister Pack Box)

Principal Display Panel (2.5 mg Cartridge Blister Pack Box)
Skytrofa 2.5 mg injection powder lyophilized for subcutaneous use, presented in a carton containing 4 single-dose cartridges and 6 sterile injection needles. Label shows brand name Skytrofa with the active ingredient Lonapegsomatropin-tcgd. Distributed by Ascendis Pharma, the packaging includes storage instructions and usage warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.